ZBIO stock news · Zenas BioPharma

Stories about Zenas BioPharma (ZBIO) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for ZBIO

Follow Zenas BioPharma (ZBIO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 31, 2026, 10:44 AM ET · Market
Zenas BioPharma shared its research plans for obexelimab and updated on its drug ZB021.
Good for ZBIO
Zenas BioPharma filed obexelimab applications in the US and Europe, and ZB021 reduced arthritis signs in animal tests. This is positive, though patient benefit remains unproven.
Oct 13, 2026, 7:54 AM ET · Market
Zenas BioPharma, Inc. shares new information about its obexelimab trial.
Neutral
Zenas BioPharma reported new Phase 3 data on obexelimab, but this filing gives no results, so it does not show a change in the company's outlook.